Sector Update: Healthcare Shares Flat; Agenus Rallies 22% on Phase 2 Cancer Treatment Study


Healthcare stocks:

JNJ: flat

PFE: flat

ABT: flat

MRK: -0.46%

AMGN: flat

Healthcare shares are flat in pre-market. Agenus Inc. ( AGEN ) is soaring 22% at $33.34 after it said its Phase 2 trial in patients with newly diagnosed glioblastoma multiforme, a form of brain cancer, treated with Prophage Series G-100 in combination with the current standard of care showed an almost 18-month median progression free survival, a 160% increase versus current standard of care alone.

Agenus plans to hold an end of Phase 2 meeting with the US Food and Drug Administration to discuss a Phase 3 trial that could potentially lead to marketing approval of the HSPPC-96 vaccine as a treatment for patients with newly diagnosed GBM.

The shares are trading near the middle of their 52-week range of $2.45 - $5.40.

And, Regado Biosciences ( RGDO ) is up 11.4% after it said it has enrolled the first patient in its REGULATE-PCI clinical trial. REGULATE-PCI is a Phase 3, PROBE design superiority study.

The trial is designed to compare the effects of RGDO's REG1 to bivalirudin in patients undergoing percutaneous coronary intervention electively or for the treatment of unstable angina or non-ST elevated myocardial infarction.

Should REGULATE-PCI be successful, the company will use it as the basis for product registration applications, expected to be filed in early 2016. The first of three key interim analyses in the trial will occur after enrollment of the first 1,000 patients and is expected to occur during Q2 of 2014.

Finally, BioLineRx ( BLRX ) said it has received a Notice of Allowance from the United States Patent and Trademark Office for BL-8020, an orally available, interferon-free treatment for hepatitis C. The patent will be valid until at least 2031.

BioLineRx is currently conducting a Phase 1/2, open-label study at two sites in France to evaluate the efficacy, safety and tolerability of BL-8020 in patients infected with HCV. The shares trade in a 52-week range of $1.55 - $5.10.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ, Inc.

Copyright (C) 2014 All rights reserved. Unauthorized reproduction is strictly prohibited.

This article appears in: Investing , Commodities

Referenced Stocks: AGEN , BLRX , RGDO

MT Newswires

MT Newswires

More from MT Newswires:

Related Videos



Most Active by Volume

  • $13.07 ▲ 10.48%
  • $5.39 ▲ 4.46%
  • $10.20 ▼ 0.39%
  • $15.6999 ▲ 0.06%
  • $27.58 ▲ 1.06%
  • $9.34 ▲ 7.48%
  • $3.89 ▼ 0.51%
  • $109.91 ▼ 1.26%
As of 10/7/2015, 01:16 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by